---
title: "Sunshine Lake Pharma Signs AI Drug R&D Framework with Shenzhen XtalPi"
description: "Sunshine Lake Pharma Signs AI Drug R&D Framework with Shenzhen XtalPi"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273785942.md"
published_at: "2026-01-27T04:12:44.000Z"
---

# Sunshine Lake Pharma Signs AI Drug R&D Framework with Shenzhen XtalPi

### Related Stocks

- [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md)
- [513060.CN - Bosera Hang Seng Health Care ETF(QDII)](https://longbridge.com/en/quote/513060.CN.md)
- [159992.CN - Yinhua CSI Innovative Drugs Industry ETF](https://longbridge.com/en/quote/159992.CN.md)
- [510660.CN - ChinaAMC SSE Health Care ETF Initiating Fund](https://longbridge.com/en/quote/510660.CN.md)
- [520690.CN - Bosera Hang Seng SCHK Innovative Drug Select ETF](https://longbridge.com/en/quote/520690.CN.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [513120.CN - GF CSI HK Innovative Drugs Industry ETF(QDII)](https://longbridge.com/en/quote/513120.CN.md)
- [159316.CN - E Fund Hang Seng SCHK Innovative Drug ETF](https://longbridge.com/en/quote/159316.CN.md)
- [02228.HK - XTALPI](https://longbridge.com/en/quote/02228.HK.md)
- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 石四藥 (2005) 發盈警料去年盈利倒退 45 至 60% | 石四藥集團發盈警，預期截至去年底止年度股東應佔溢利按年下跌 45 至 60%；2024 年度錄得股東應佔溢利 10.61 億港元。 | [Link](https://longbridge.com/en/news/276431030.md) |
| 埃隆·馬斯克的 Neuralink 在中國激發了腦機接口技術的競賽 | Neuralink，由埃隆·馬斯克創立，正在推動中國腦機接口（BCI）發展的熱潮，像 NeuroXess 這樣的初創公司迅速進入人體試驗階段。NeuroXess 於 2021 年成立，已經在患者身上測試植入物。中國政府已將 BCI 列為戰略 | [Link](https://longbridge.com/en/news/276460367.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.